CN117529490A - 用于将药物递送至肝细胞的环状肽-N-乙酰半乳糖胺（GalNAc）缀合物 - Google Patents

用于将药物递送至肝细胞的环状肽-N-乙酰半乳糖胺（GalNAc）缀合物 Download PDF

Info

Publication number
CN117529490A
CN117529490A CN202280043909.8A CN202280043909A CN117529490A CN 117529490 A CN117529490 A CN 117529490A CN 202280043909 A CN202280043909 A CN 202280043909A CN 117529490 A CN117529490 A CN 117529490A
Authority
CN
China
Prior art keywords
cpmb
conjugate
linker
cyclic peptide
fam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280043909.8A
Other languages
English (en)
Chinese (zh)
Inventor
张翼中
陈慧瑜
杨奇凡
陈怀懿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongtian Shanghai Biotechnology Co ltd
Original Assignee
Zhongtian Shanghai Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhongtian Shanghai Biotechnology Co ltd filed Critical Zhongtian Shanghai Biotechnology Co ltd
Publication of CN117529490A publication Critical patent/CN117529490A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280043909.8A 2021-04-23 2022-04-21 用于将药物递送至肝细胞的环状肽-N-乙酰半乳糖胺（GalNAc）缀合物 Pending CN117529490A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/089305 2021-04-23
CN2021089305 2021-04-23
PCT/CN2022/088117 WO2022222986A1 (en) 2021-04-23 2022-04-21 Cyclic peptide-n-acetylgalactosamine (galnac) conjugates for drug delivery to liver cells

Publications (1)

Publication Number Publication Date
CN117529490A true CN117529490A (zh) 2024-02-06

Family

ID=83723528

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280043909.8A Pending CN117529490A (zh) 2021-04-23 2022-04-21 用于将药物递送至肝细胞的环状肽-N-乙酰半乳糖胺（GalNAc）缀合物

Country Status (9)

Country Link
US (1) US20240218023A1 (https=)
EP (1) EP4326744A1 (https=)
JP (1) JP2024516613A (https=)
KR (1) KR20240044385A (https=)
CN (1) CN117529490A (https=)
AU (1) AU2022261265A1 (https=)
IL (1) IL307882A (https=)
WO (1) WO2022222986A1 (https=)
ZA (1) ZA202309922B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024117938A1 (ru) * 2022-11-30 2024-06-06 Общество с ограниченной ответственностью "СИСТЕМА-БИОТЕХ" Способы получения биоконъюгатов для печень-специфической направленной модуляции протеома
WO2024152775A1 (zh) * 2023-01-17 2024-07-25 云合智药（苏州）生物科技有限公司 缀合物、配体单元及其用途
TW202517784A (zh) * 2023-07-14 2025-05-01 大陸商云合智藥（蘇州）生物科技有限公司 用於抑制己酮糖激酶表達的ＲＮＡｉ劑及其應用
CN120040554B (zh) * 2025-04-25 2025-07-18 云合智药（苏州）生物科技有限公司 环肽类肝靶向化合物、药物组合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
US11987647B2 (en) * 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues

Also Published As

Publication number Publication date
JP2024516613A (ja) 2024-04-16
ZA202309922B (en) 2025-05-28
EP4326744A1 (en) 2024-02-28
IL307882A (en) 2023-12-01
US20240218023A1 (en) 2024-07-04
AU2022261265A1 (en) 2023-11-09
AU2022261265A9 (en) 2023-11-16
WO2022222986A1 (en) 2022-10-27
KR20240044385A (ko) 2024-04-04

Similar Documents

Publication Publication Date Title
CN117529490A (zh) 用于将药物递送至肝细胞的环状肽-N-乙酰半乳糖胺（GalNAc）缀合物
JP7174757B2 (ja) 切断可能なリンカーを含む化合物及びその使用
CA3142960C (en) A formulation of a conjugate of a tubulysin analog to a cell-binding molecule
ES2906109T3 (es) Ligandos de la integrina alfa- v beta-6 y usos de los mismos
WO2019199634A1 (en) Bifunctional small molecules to target the selective degradation of circulating proteins
EP3030244B1 (en) Polyconjugates for delivery of rnai triggers to tumor cells in vivo
TW200815452A (en) Aziridinyl-epothilone compounds
CN103402545A (zh) 疏水性经修饰肽及其在肝特异性靶向中的用途
US20240165245A1 (en) Multivalent peptoid oligomers, pharmaceutical compositions and methods of using same
JP2025063139A (ja) リンカー
WO2012092373A2 (en) In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
CN111001012A (zh) 一种亲水碳酸酯型抗体偶联药物
JP2020535171A (ja) 去勢抵抗性前立腺癌
CN116056765A (zh) 反式环辛烯生物正交剂及在癌症和免疫疗法中的用途
JP2021503441A (ja) Ｐｅｇ化されたカルフィルゾミブ化合物の安定組成物
JP2016523825A (ja) 腎毒性活性物質からの保護のための接合体
WO2023045995A1 (en) Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents
TW202400788A (zh) 用於靶向遞送治療劑的雙環雜環及其配體
EP3383437A1 (en) Mmp-sensitive taxane prodrug
WO2020014652A1 (en) Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
WO2025201467A1 (zh) 用于抑制中枢神经系统靶基因表达的多肽寡核苷酸缀合物及其应用
JP7709164B2 (ja) 核酸送達促進剤
WO2025261376A1 (zh) 肝外递送配体及其缀合物
WO2025067354A1 (zh) 抑制淀粉样前体蛋白(APP)基因表达的siRNA、药物及其应用
JPWO2015186785A1 (ja) 生体内のアシル化機能と置き換えられる人工触媒システム

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination